Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07356245 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
A Phase 2 study of Graft-Versus-Host Disease and Peripheral T-Cell Lymphoma, sponsored by Jonathan Brammer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT07356245: Recruiting Phase 2 study of Graft-Versus-Host Disease and Peripheral T-Cell Lymphoma, sponsored by Jonathan Brammer.
NCT07356245 is a Phase 2 study of Graft-Versus-Host Disease and Peripheral T-Cell Lymphoma that is actively recruiting participants, run by Jonathan Brammer. The registered enrollment target is 44 participants, below the 82-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07356245, a Phase 2 study of Graft-Versus-Host Disease and Peripheral T-Cell Lymphoma, is actively recruiting participants, sponsored by Jonathan Brammer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The "graft" is the donor blood cells that patients get during the transplant. The "host" is the person receiving the cells. GVHD is when the donor graft attacks and damages some of the transplant recipient's tissues. Ruxolitinib is a type of drug called a Janus kinase (JAK) inhibitor which works by decreasing the immune response of cells in the body. It is also a cancer growth blocker that blocks the growth factors that trigger the cancer cells to divide and grow. Ruxolitinib works by blocking a gene, called JAK2, that is important in the production of cancer cells.
Primary Outcome
Relapse is defined as evidence of disease progression or recurrence based on Lugano criteria or confirmed by biopsy.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Bone Marrow Biopsy
- PROCEDURE Biopsy Procedure
- DRUG Ruxolitinib
- PROCEDURE Positron emission tomography-computed tomography
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 2 |
What NCT07356245 shows while recruiting
NCT07356245 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 82-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (46% lower).
The record links to 8 conditions, with Graft-Versus-Host Disease appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07356245 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07356245 about?
NCT07356245 is a clinical study titled "Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma". This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The "gra...
What is the current status of trial NCT07356245?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2026-02-01. Estimated completion is 2027-01-31.
What conditions does trial NCT07356245 study?
This clinical trial studies the following conditions: Graft-Versus-Host Disease, Peripheral T-Cell Lymphoma, Cutaneous T Cell Lymphoma, T-Cell Lymphoma, Lymphoma, T-Cell.
What interventions are being tested in trial NCT07356245?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Biopsy Procedure (PROCEDURE), Ruxolitinib (DRUG), Positron emission tomography-computed tomography (PROCEDURE).
Who is sponsoring clinical trial NCT07356245?
This trial is sponsored by Jonathan Brammer, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07356245 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft-Versus-Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07356245's enrollment target sits among peer trials
44 16th of 38 higher than 22 of 38 other Graft-Versus-Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Graft-Versus-Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
RECRUITING · Phase 2
-
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RECRUITING · Phase 2
-
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
RECRUITING · Phase 2
-
Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant
ACTIVE NOT RECRUITING · Phase 2
-
De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
ACTIVE NOT RECRUITING · Phase 2
-
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI